1003 – Impact of the COVID-19 pandemic on breast cancer mortality rates: a temporal analysis from 2020 to 2024
DOI:
https://doi.org/10.29289/25945394V36S11003Keywords:
breast neoplasms, COVID-19, Epidemiology, delayed diagnosis, time-to-treatmentAbstract
Introduction/Justification: The COVID-19 pandemic severely disrupted oncology screening and care. This study evaluates the impact of the pandemic on breast cancer diagnostic staging and waiting times for initial treatment among
Brazilian women.
Methods: A retrospective ecological study was conducted using public data from the Brazilian Ministry of Health
(DATASUS, INCA Hospital Cancer Registry – RHC, and Oncology Panel). Extracted data included female population estimates and breast cancer mortality (2015–2024), clinical staging of analytical cases (2015–2023), and time to first treatment
(2021–2024). AI tools (Gemini) were used exclusively for mathematical percentage calculations and English translation.
Results: Between 2015 and 2024, 179,917 deaths from breast cancer were recorded. Analysis of the INCA RHC database
revealed that the proportion of advanced-stage diagnoses (Stages III and IV) rose from 28.6% in the pre-pandemic period
(2015–2019) to 30.6% during and after the peak of the pandemic (2020–2023). Furthermore, regarding the 60-day legal
limit for starting treatment, the Oncology Panel data showed that 46.1% of patients waited more than 60 days for their
first oncological treatment in 2021, compared to 55.4% in 2024.
Conclusion: The pandemic period was associated with a higher proportion of late-stage breast cancer diagnoses and significant, progressive delays in treatment. These findings highlight a critical bottleneck in the public health system and the
urgent need for strategic policies to reduce the accumulated pent-up demand for oncological care.
Ethics: Public data.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Jean Karlus Rocha de Souza, Nicole Marques Santos, Marina Elias Rocha

This work is licensed under a Creative Commons Attribution 4.0 International License.






